United Therapeutics Corporation
Price Action
Technical Summary
STAGE 2 UPTRENDUnited Therapeutics Corporation is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is moderate (RS Rating: 61), indicating performance broadly in line with the market. Earnings contraction of 12% provides fundamental context to the price action. Momentum will need to be maintained above the 50-day moving average to sustain this leadership phase.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $546.93 | +3.07% | ABOVE |
| 50 SMA | $558.92 | +0.86% | ABOVE |
| 100 SMA | $545.91 | +3.26% | ABOVE |
| 150 SMA | $525.97 | +7.17% | ABOVE |
| 200 SMA | $505.66 | +11.48% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is UTHR in an uptrend right now?
UTHR has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, UTHR is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is UTHR overbought or oversold?
UTHR's RSI (14) is 48. The stock is in neutral territory, neither overbought nor oversold.
Is UTHR outperforming the market?
UTHR has a Relative Strength (RS) Rating of 61 out of 99. UTHR is performing about average compared to the market.
Where is UTHR in its 52-week range?
UTHR is trading at $563.70, which is 93% of its 52-week high ($609.35) and 86% above its 52-week low ($272.12).
How volatile is UTHR?
UTHR has a Beta of 0.09 and 52-week volatility of 47%. It's less volatile than the S&P 500 - generally more stable.